Background: Antiphospholipid antibodies (aPLs) namely anticardiolipin (aCL) antibody, anti-beta 2-glycoprotein I (beta 2GPI) antibody and lupus anticoagulant (LA) are autoantibodies produced against anionic phospholipids and proteins on plasma membranes. Migraine is a primary headache disorder which has growing evidences of autoimmune-mediated pathogenesis and previous studies suggested the presence of aPLs in migraine patients. Aims: The aim of this study was to evaluate the comorbid association between aPLs (aCL, anti-beta 2GPI and LA) and migraine compared to healthy controls. Methods: Studies were searched through PubMed, ISI Web of Science and Google Scholar databases without restricting the languages and year (up to October 2016) and were selected based on the inclusion criteria. Two authors independently extracted data from the included studies. All analyses were conducted by using random effects model to calculate the odds ratio (OR) and 95% confidence interval (CI). Quality assessment was carried out by using themodified Newcastle-Ottawa Scale (NOS). Publication bias was evaluated via visualization of funnel plots, Begg's and Egger's tests. Results: The database searches produced 1995 articles, 13 of which were selected (912 migraineurs and 822 healthy controls). 8.59%, 15.21% and 4.11% of the migraineurs exhibited aCL, anti-beta 2GPI and LA which was 4.83, 1.63 and 3.03 times higher, respectively, than healthy controls. A significant presence of aCL (OR: 3.55, 95% CI: 1.59-7.95; p = 0.002) or anti-beta 2GPI antibodies (OR: 2.02, 95% CI: 1.20-3.42; p = 0.008) was observed in migraine patients, however, LA was not significantly associated (OR: 2.02, 95% CI: 0.50-8.37; p = 0.320). Majority of the studies (n = 10 of 13) demonstrated NOS score of 7 or above and no significant publication biaswas observed. Conclusion: Migraine might be an autoimmune-associated neurologic disorder. The presence of aCL or anti-beta 2GPI antibodies was significant in migraine patients compared to healthy controls, suggesting an involvement of these autoantibodies in migraine attack. (C) 2017 Elsevier B.V. All rights reserved.